ProShares Ultra NASDAQ Biotechnology
28 hedge funds and large institutions have $39.2M invested in ProShares Ultra NASDAQ Biotechnology in 2015 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 7 reducing their positions, and 6 closing their positions.
57% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 7
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
3% less funds holding
Funds holding: 29 → 28 (-1)
7% less capital invested
Capital invested by funds: $42.3M → $39.2M (-$3.13M)
73% less call options, than puts
Call options by funds: $8.52M | Put options by funds: $31M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SG Americas Securities
New York
|
+$608K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$465K |
| 3 |
BFC
Blue Fin Capital
Warren,
Rhode Island
|
+$355K |
| 4 |
VCAM
Valentine Capital Asset Management
Danville,
California
|
+$343K |
| 5 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$282K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AP
Advisors Preferred
Rockville,
Maryland
|
-$3.35M |
| 2 |
OPPM
Opus Point Partners Management
New York
|
-$3.03M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.24M |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.98M |
| 5 |
Jane Street
New York
|
-$916K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TCM
26
Tradewinds Capital Management
Bellingham,
Washington
| $2K | – | – | – |
|
|
PFG
27
Piershale Financial Group
Barrington,
Illinois
| $2K | +$2.08K | +28 | New |
|
|
28
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$2.24M | -30,228 | Closed |
|
|
ACP
29
Aviance Capital Partners
Naples,
Florida
| – | -$682K | -10,870 | Closed |
|
30
Goldman Sachs
New York
| – | -$392K | -6,246 | Closed |
|
|
GT
31
Glenmede Trust
Philadelphia,
Pennsylvania
| – | -$69K | -1,100 | Closed |
|
32
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$13K | -200 | Closed |
|
|
SSG
33
Summit Securities Group
New York
| – | -$13K | -200 | Closed |
|
BIB Hedge Fund Activity: Q1 2015 in Review
28 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q1 2015, worth a combined $39.2M — down 7.4% from $42.3M a quarter earlier.
Fund positioning in BIB was balanced in Q1 2015: 6 funds opened new positions, 6 closed out, 11 added to existing stakes and 7 trimmed.
The largest buyer was SG Americas Securities, opening a new position worth an estimated $608K. The largest seller was Advisors Preferred, cutting an estimated $3.35M.
- 28 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q1 2015, down from 29 in Q4 2014.
- Funds reported $39.2M of ProShares Ultra NASDAQ Biotechnology stock for Q1 2015, down 7.4% quarter-over-quarter.
- 6 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q1 2015 and 6 closed out, a net change of 0 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q1 2015 was SG Americas Securities, an estimated $608K added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q1 2015 was Advisors Preferred, an estimated $3.35M sold.
Based on aggregated 13F filings for Q1 2015.